Clinical trials
Phase 2 Delirium trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 23 |
| Unknown status | 4 |
| Withdrawn | 4 |
| Recruiting | 3 |
| Terminated | 2 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Colorado, Denver | 2 |
| University of Rochester | 2 |
| Vanderbilt University | 2 |
| Ain Shams University | 1 |
| Air Liquide Santé International | 1 |
| Antonia New | 1 |
| Assiut University | 1 |
| Austin Health | 1 |
| Beth Israel Deaconess Medical Center | 1 |
| BioXcel Therapeutics Inc | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Delirium | 38 |
| Cognitive Dysfunction | 10 |
| Emergence Delirium | 6 |
| Alzheimer Disease | 4 |
| Critical Illness | 4 |
| Dementia | 4 |
| Psychomotor Agitation | 4 |
| Hip Fractures | 3 |
| Mental Disorders | 3 |
| Postoperative Cognitive Complications | 3 |
Trials
Showing 26 to 38 of 38. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.